3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
23
Squamous Cell Carcinoma of Head and Neck
10
Melanoma
8
Lung Neoplasms
8
Neoplasms
7
Carcinoma
6
Skin Neoplasms
5
Neoplasm Metastasis
5
Carcinoma, Squamous Cell
5
Carcinoma, Basal Cell
5
Adenocarcinoma
5
Sarcoma
4
Mouth Neoplasms
4
Head and Neck Neoplasms
4
Colonic Neoplasms
4
Carcinoma, Renal Cell
4
Urinary Bladder Neoplasms
3
Recurrence
3
Oropharyngeal Neoplasms
3
Laryngeal Neoplasms
3
Carcinoma, Merkel Cell
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Rectal Neoplasms
2
Pancreatic Neoplasms
2
Mesothelioma, Malignant
2
Hemangiosarcoma
2
Glioblastoma
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Interventions
durvalumab
5
Nivolumab
3
Cyclophosphamide
3
Cisplatin
3
130-nm albumin-bound paclitaxel
3
padeliporfin
2
anlotinib
2
Trabectedin
2
Sunitinib
2
Pemetrexed
2
Docetaxel
2
Chemoradiotherapy
2
Carboplatin
2
Bevacizumab
2
sotorasib
1
relatlimab
1
relacorilant
1
pembrolizumab
1
patritumab
1
palbociclib
1
olaparib
1
niraparib
1
nintedanib
1
montanide ISA 51
1
golotimod
1
genexol-PM
1
ceralasertib
1
cemiplimab
1
camrelizumab
1
atezolizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms by Site
×
cemiplimab
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled